Chitosan-based nanoparticles for improved anticancer efficacy and bioavailability of mifepristone

• Huijuan Zhang,
• Fuqiang Wu,
• Yazhen Li,
• Xiping Yang,
• Jiamei Huang,
• Tingting Lv,
• Yingying Zhang,
• Jianzhong Chen,
• Haijun Chen,
• Yu Gao,
• Guannan Liu and
• Lee Jia

Beilstein J. Nanotechnol. 2016, 7, 1861–1870, doi:10.3762/bjnano.7.178

• , College of Life Sciences, China Jiliang University, Hangzhou, Zhejiang, 310018, China 10.3762/bjnano.7.178 Abstract In addition to its well-known abortifacient effect, mifepristone (MIF) has been used as an anticancer drug for various cancers in many studies with an in-depth understanding of the

• curve from 0 to 24 h compared with free MIF. These results demonstrated that MCNs could be developed as a potential delivery system for MIF to improve its anticancer activity and bioavailability. Keywords: anticancer; chitosan; drug delivery; mifepristone; nanoparticles; pharmacokinetics; sustained

• release; Introduction Mifepristone (RU486, MIF) acts as a progesterone receptor (PR) modulator and has been widely used for emergency contraception and to provoke early-stage abortion [1][2]. Recently, it has been approved by the Federal Drug Administration (FDA) to treat hyperglycemia associated with